Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
paper
Cited
Public
Unavailable
- Authors
- Schoedel, Kerri A; Hoffmann, Ewa B; Rao, Yushu; Sellers, Edward M; Tyndale, Rachel F
- Year
- 2004
- Journal
- Pharmacogenetics
- PMID
- 15475735
- DOI
- 10.1097/00008571-200409000-00006
Genetically variable CYP2A6 is the primary enzyme that inactivates nicotine to cotinine. Our objective was to investigate allele frequencies among five ethnic groups and to investigate the relationship between genetically slow nicotine metabolic inactivation and smoking status, cigarette consumption, age of first smoking and duration of smoking. Chinese, Japanese, Canadian Native Indian, African-North American and Caucasian DNA samples were assessed for CYP2A6 allelic frequencies (CYP2A6*1B-*12,*1x2). Adult Caucasian non-smokers (n = 224) (1-99 cigarettes/lifetime) and smokers (n = 375) (> or = 100 cigarettes/lifetime) were assessed for demographics, tobacco/drug use history and DSM-IV dependence and genotyped for CYP2A6 alleles associated with decreased nicotine metabolism (CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12). CYP2A6 allele frequencies varied substantially among the ethnic groups. The proportion of Caucasian slow nicotine inactivators was significantly lower in current, DSM-IV dependent smokers compared to non-smokers [7.0% and 12.5%, respectively, P = 0.03, odds ratio (OR) = 0.52; 95% confidence interval (CI) 0.29-0.95]; non-dependent smokers showed similar results. Daily cigarette consumption (cigarettes/day) was significantly (P = 0.003) lower for slow (21.3; 95% CI 17.4-25.2) compared to normal inactivators (28.2; 95% CI 26.4-29.9); this was observed only in DSM-IV dependent smokers. Slow inactivators had a significantly (P = 0.03) lower age of first smoking compared to normal inactivators (13.0 years of age; 95% CI 12.1-14.0 versus 14.2; 95% CI 13.8-14.6), and a trend towards smoking for a shorter duration. This study demonstrates that slow nicotine inactivators are less likely to be adult smokers (dependent or non-dependent). Slow inactivators also smoked fewer cigarettes per day and had an earlier age of first smoking (only dependent smokers).
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Inhibition of CYP2A6-mediated nicotine metabolism: A potential strategy for smoking cessation therapy. | Olawale ME et al. | β | 2026 | β |
| A phenome-wide association study of genetically determined nicotine metabolism reveals novel links with health-related outcomes. | Buchwald J et al. | β | 2025 | β |
| Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community. | Wichman ML et al. | β | 2025 | β |
| Impact of CYP2A6 Gene Polymorphism on the Efficacy and Safety of S-1 Therapy in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis. | Dong T et al. | β | 2024 | β |
| Single Nucleotide Polymorphisms Within <i>DRD2, COMT, and DBH</i> and Smoking Cessation: A Systematic Review Considering Genetic Differences by Ancestry and Biological Sex. | Jones SK et al. | β | 2024 | β |
| The Role of Nicotine Metabolic Rate on Nicotine Dependence and Rewarding: Nicotine Metabolism in Chinese Male Smokers and Male Mice. | Liu M et al. | β | 2024 | β |
| Risk factors for the development of second primary esophageal squamous-cell carcinoma after endoscopic resection for esophageal squamous-cell carcinoma according to genetic polymorphisms related to alcohol and nicotine metabolism. | Katada C et al. | β | 2023 | β |
| Effects of Genetic Variants in the Nicotine Metabolism Pathway on Smoking Cessation. | Li H et al. | β | 2022 | β |
| Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes. | El-Boraie A et al. | β | 2022 | β |
| Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review. | Jones SK et al. | β | 2022 | β |
| Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine. | Ahire D et al. | β | 2022 | β |
| Nicotine addiction: Translational insights from circuit neuroscience. | Scarlata MJ et al. | β | 2021 | β |
| Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke. | Schaefer KR et al. | β | 2021 | β |
| Polytobacco use among a nationally-representative sample of black high school students. | Gilreath TD et al. | β | 2021 | β |
| The reinforcement threshold and elasticity of demand for nicotine in an adolescent rat model of depression. | Smethells JR et al. | β | 2021 | β |
| Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. | El-Boraie A et al. | β | 2021 | β |
| Association of CYP2A6 gene deletion with cancers in Japanese elderly: an autopsy study. | Abudushataer M et al. | β | 2020 | β |
| Comparison of Liquid Chromatography Mass Spectrometry and Enzyme-Linked Immunosorbent Assay Methods to Measure Salivary Cotinine Levels in Ill Children. | Mahabee-Gittens EM et al. | β | 2020 | β |
| Divergent trends in lifetime drinking and smoking between Black and White Americans diagnosed with chronic pancreatitis. | Jeon CY et al. | β | 2020 | β |
| Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. | El-Boraie A et al. | β | 2020 | β |
| Genetic variants in CYP2A6 and UGT1A9 genes associated with urinary nicotine metabolites in young Mexican smokers. | Borrego-Soto G et al. | β | 2020 | β |
| Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis. | Yoon HY et al. | β | 2020 | β |
| Nicotine in Senescence and Atherosclerosis. | Centner AM et al. | β | 2020 | β |
| Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. | Claw KG et al. | β | 2020 | β |
| Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults. | Stancil SL et al. | β | 2019 | β |
| Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population. | Ezzeldin N et al. | β | 2018 | β |
| Biochemical, demographic, and self-reported tobacco-related predictors of the acute heart rate response to nicotine in smokers. | Jensen KP et al. | β | 2018 | β |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | β | 2018 | β |
| Functional Neurocircuits and Neuroimaging Biomarkers of Tobacco Use Disorder. | Sutherland MT et al. | β | 2018 | β |
| Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers. | Di Ciano P et al. | β | 2018 | β |
| P450 Pharmacogenetics in Indigenous North American Populations. | Henderson LM et al. | β | 2018 | β |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | β | 2018 | β |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | β | 2018 | β |
| Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment. | Bozinoff N et al. | β | 2018 | β |
| Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors. | Chen LS et al. | β | 2018 | β |
| Acculturation, Depression, and Smoking Cessation: a trajectory pattern recognition approach. | Kim SS et al. | β | 2017 | β |
| Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer. | Jeong JH et al. | β | 2017 | β |
| Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of Stop Smoking Services in England. | Shahab L et al. | β | 2017 | β |
| CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers. | Li S et al. | β | 2017 | β |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | LΓ³pez-Flores LA et al. | β | 2017 | β |
| Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. | Taghavi T et al. | β | 2017 | β |
| Genetic polymorphisms in CYP2A6 are associated with a risk of cigarette smoking and predispose to smoking at younger ages. | PΓ©rez-Rubio G et al. | β | 2017 | β |
| Interaction between cytochrome P450 2A6 and Catechol-O-Methyltransferase genes and their association with smoking risk in young men. | Ou WC et al. | β | 2017 | β |
| Is individual smoking behaviour influenced by area-level ethnic density? A cross-sectional electronic health database study of inner south-east London. | Mathur R et al. | β | 2017 | β |
| Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. | Wang LA et al. | β | 2017 | β |
| MIFuzzy Clustering for Incomplete Longitudinal Data in Smart Health. | Fang H | β | 2017 | β |
| Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers. | Borrie AE et al. | β | 2017 | β |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | β | 2017 | β |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | β | 2017 | β |
| Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. | Tanner JA et al. | β | 2017 | β |
| Validation of an Arabic version of an instrument to measure waterpipe smoking behavior. | Abou Arbid S et al. | β | 2017 | β |
| Variation in CYP2A6 Activity and Personalized Medicine. | Tanner JA et al. | β | 2017 | β |
| Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. | Tanner JA et al. | β | 2017 | β |
| Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting. | Fogli S et al. | β | 2016 | β |
| Genetic Risk Determinants for Cigarette Smoking Dependence in Mexican Mestizo Families. | Svyryd Y et al. | β | 2016 | β |
| Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. | Chan J et al. | β | 2016 | β |
| Multiple- vs Non- or Single-Imputation based Fuzzy Clustering for Incomplete Longitudinal Behavioral Intervention Data. | Zhang Z et al. | β | 2016 | β |
| Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. | Ross KC et al. | β | 2016 | β |
| The Influence of Puff Characteristics, Nicotine Dependence, and Rate of Nicotine Metabolism on Daily Nicotine Exposure in African American Smokers. | Ross KC et al. | β | 2016 | β |
| Variation in CYP2A6 and tobacco dependence throughout adolescence and in young adult smokers. | Chenoweth MJ et al. | β | 2016 | β |
| A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. | Jensen KP et al. | β | 2015 | β |
| Association of CYP2A6 gene polymorphisms with cigarette consumption: a meta-analysis. | Pan L et al. | β | 2015 | β |
| Cohort Profile: The Nicotine Dependence in Teens (NDIT) Study. | O'Loughlin J et al. | β | 2015 | β |
| CYP2A6 genetic polymorphism is associated with decreased susceptibility toΒ squamous cell lung cancer in Japanese smokers. | Hosono H et al. | β | 2015 | β |
| Is there evidence for potential harm of electronic cigarette use in pregnancy? | Suter MA et al. | β | 2015 | β |
| N-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth cohort. | LeMasters GK et al. | β | 2015 | β |
| Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine. | ΔoliΔ A et al. | β | 2015 | β |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | β | 2015 | β |
| Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. | Hamilton DA et al. | β | 2015 | β |
| The allele frequency of CYP2A6*4 in four ethnic groups of China. | Pang C et al. | β | 2015 | β |
| Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. | Bagdas D et al. | β | 2014 | β |
| Interpatient variability in dexmedetomidine response: a survey of the literature. | Holliday SF et al. | β | 2014 | β |
| Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. | Chenoweth MJ et al. | β | 2014 | β |
| Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. | Piliguian M et al. | β | 2014 | β |
| Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). | Chen LS et al. | β | 2014 | β |
| Plasma cotinine levels in cigarette smokers: impact of mental health and other correlates. | Bot M et al. | β | 2014 | β |
| Priority pharmacogenetics for the African continent: focus on CYP450. | Alessandrini M et al. | β | 2014 | β |
| Rational design of novel CYP2A6 inhibitors. | Tani N et al. | β | 2014 | β |
| Single tube genotyping of CYP2A6 gene deletion based on copy number determination by quantitative real-time PCR. | Liu JH et al. | β | 2014 | β |
| Smoking behaviour and compensation: a review of the literature with meta-analysis. | Scherer G et al. | β | 2014 | β |
| The Genetics, Neurogenetics and Pharmacogenetics of Addiction. | Demers CH et al. | β | 2014 | β |
| Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. | Chenoweth MJ et al. | β | 2014 | β |
| Advances in molecular modeling of human cytochrome P450 polymorphism. | Martiny VY et al. | β | 2013 | β |
| Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. | Zhu AZ et al. | β | 2013 | β |
| Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies. | Liu T et al. | β | 2013 | β |
| Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers. | Liu T et al. | β | 2013 | β |
| Biomarkers for smoking cessation. | Bough KJ et al. | β | 2013 | β |
| Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. | Djordjevic N et al. | β | 2013 | β |
| CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. | Liu YL et al. | β | 2013 | β |
| CYP2A6 genotype but not age determines cotinine half-life in infants and children. | Dempsey DA et al. | β | 2013 | β |
| Cytochrome P450 pharmacogenetics in African populations. | Alessandrini M et al. | β | 2013 | β |
| Determination of nicotine absorption from multiple tobacco products and nicotine gum. | Digard H et al. | β | 2013 | β |
| Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. | Dempsey DA et al. | β | 2013 | β |
| Nicotine metabolism and addiction among adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| Pharmacogenetics of chronic obstructive pulmonary disease. | Hizawa N | β | 2013 | β |
| Race, gender, and nicotine metabolism in adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. | Zhu AZ et al. | β | 2013 | β |
| The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans. | Bloom AJ et al. | β | 2013 | β |
| Application of the buccal micronucleus cytome assay and analysis of PON1Gln192Arg and CYP2A6*9(-48T>G) polymorphisms in tobacco farmers. | Da Silva FR et al. | β | 2012 | β |
| CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. | Binnington MJ et al. | β | 2012 | β |
| CYP2A6 genetic variation and dexmedetomidine disposition. | Kohli U et al. | β | 2012 | β |
| Cytochrome P450 variations in different ethnic populations. | McGraw J et al. | β | 2012 | β |
| Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. | Tang DW et al. | β | 2012 | β |
| Haplotypes with copy number and single nucleotide polymorphisms in CYP2A6 locus are associated with smoking quantity in a Japanese population. | Kumasaka N et al. | β | 2012 | β |
| Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis. | Momi N et al. | β | 2012 | β |
| Nicotine vaccines to assist with smoking cessation: current status of research. | Raupach T et al. | β | 2012 | β |
| Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. | Gold AB et al. | β | 2012 | β |
| PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | McDonagh EM et al. | β | 2012 | β |
| Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers. | Liu T et al. | β | 2012 | β |
| Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. | Portugal GS et al. | β | 2012 | β |
| Superior methadone treatment outcome in Hmong compared with non-Hmong patients. | Bart G et al. | β | 2012 | β |
| The genetics of substance dependence. | Wang JC et al. | β | 2012 | β |
| Tobacco use and suicidality: latent patterns of co-occurrence among black adolescents. | Gilreath TD et al. | β | 2012 | β |
| Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. | Bloom AJ et al. | β | 2012 | β |
| Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. | Wang H et al. | β | 2011 | β |
| Associations of CYP2A6 genotype with smoking behaviors in southern China. | Liu T et al. | β | 2011 | β |
| CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. | Park SR et al. | β | 2011 | β |
| Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. | Cox LS et al. | β | 2011 | β |
| Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations. | Soriano A et al. | β | 2011 | β |
| Genetic vulnerability and susceptibility to substance dependence. | Bierut LJ | β | 2011 | β |
| Identification of novel CYP2A6 inhibitors by virtual screening. | Rahnasto MK et al. | β | 2011 | β |
| Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. | Liu T et al. | β | 2011 | β |
| Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. | Kim KP et al. | β | 2011 | β |
| Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). | Lopez-Quintero C et al. | β | 2011 | β |
| 'Smoking genes': a genetic association study. | Verde Z et al. | β | 2011 | β |
| The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. | Bloom J et al. | β | 2011 | β |
| Association between nicotine metabolism and CYP2A6*1 and CYP2A6*4 genotypes in an Iranian population. | Heravi RE et al. | β | 2010 | β |
| Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? | Ishii Y et al. | β | 2010 | β |
| Epidemiology, determinants, and consequences of cigarette smoking in African American women: an integrative review. | Mickens L et al. | β | 2010 | β |
| Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. | Lerman C et al. | β | 2010 | β |
| Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. | Al Koudsi N et al. | β | 2010 | β |
| Investigation of binding features: effects on the interaction between CYP2A6 and inhibitors. | Ai C et al. | β | 2010 | β |
| New CYP2A6 gene deletion and conversion variants in a population of Black African descent. | Mwenifumbo JC et al. | β | 2010 | β |
| Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. | Berg JZ et al. | β | 2010 | β |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| Pharmacogenomics of maternal tobacco use: metabolic gene polymorphisms and risk of adverse pregnancy outcomes. | Aagaard-Tillery K et al. | β | 2010 | β |
| The Role of Genetics in Nicotine Dependence: Mapping the Pathways from Genome to Syndrome. | Mackillop J et al. | β | 2010 | β |
| UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. | Berg JZ et al. | β | 2010 | β |
| 5HTT polymorphisms are associated with job stress in Japanese workers. | Katsuyama H et al. | β | 2009 | β |
| A link between adolescent nicotine metabolism and smoking topography. | Moolchan ET et al. | β | 2009 | β |
| A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. | Al Koudsi N et al. | β | 2009 | β |
| Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. | Kong SY et al. | β | 2009 | β |
| Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. | Ho MK et al. | β | 2009 | β |
| Environmental influences on epigenetic profiles. | Suter MA et al. | β | 2009 | β |
| Gene-gene interactions of CYP2A6 and MAOA polymorphisms on smoking behavior in Chinese male population. | Tang X et al. | β | 2009 | β |
| Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. | Swan GE et al. | β | 2009 | β |
| Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? | Quaak M et al. | β | 2009 | β |
| High prevalence of CYP2A6*4 and CYP2A6*9 alleles detected among a Malaysian population. | Yusof W et al. | β | 2009 | β |
| Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases. | Quaak M et al. | β | 2009 | β |
| Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. | Ray R et al. | β | 2009 | β |
| Polymorphism of human cytochrome P450 enzymes and its clinical impact. | Zhou SF et al. | β | 2009 | β |
| Polymorphisms in metabolic genes CYP1A1 and GSTM1 and changes in maternal smoking during pregnancy. | Chen X et al. | β | 2009 | β |
| Rapid detection of the CYP2A6*12 hybrid allele by Pyrosequencing technology. | Koontz DA et al. | β | 2009 | β |
| A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. | Ho MK et al. | β | 2008 | β |
| CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. | Sinues B et al. | β | 2008 | β |
| CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. | Fujita K et al. | β | 2008 | β |
| Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. | Katz DA et al. | β | 2008 | β |
| Growth hormone does not alter CYP2A6 activity in growth hormone-deficient children. | SinuΓ©s B et al. | β | 2008 | β |
| Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach. | Rahnasto M et al. | β | 2008 | β |
| Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. | Mwenifumbo JC et al. | β | 2008 | β |
| Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. | Mwenifumbo JC et al. | β | 2008 | β |
| Race and nicotine replacement treatment outcomes among low-income smokers. | Fu SS et al. | β | 2008 | β |
| Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. | Rubinstein ML et al. | β | 2008 | β |
| Smoking cessation: significance and implications for children. | Borchers AT et al. | β | 2008 | β |
| Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. | Mwenifumbo JC et al. | β | 2008 | β |
| The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. | Kaida Y et al. | β | 2008 | β |
| The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. | Yasuda SU et al. | β | 2008 | β |
| Tobacco addiction. | Hatsukami DK et al. | β | 2008 | β |
| Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. | Patterson F et al. | β | 2008 | β |
| A cross-cultural and historical survey of tobacco use among various ethnic groups. | Stolberg VB | β | 2007 | β |
| A novel duplication type of CYP2A6 gene in African-American population. | Fukami T et al. | β | 2007 | β |
| Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. | David SP et al. | β | 2007 | β |
| Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. | Siu EC et al. | β | 2007 | β |
| CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. | Lee AM et al. | β | 2007 | β |
| CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. | Lee AM et al. | β | 2007 | β |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | β | 2007 | β |
| Guidelines on nicotine dose selection for in vivo research. | Matta SG et al. | β | 2007 | β |
| Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. | Damaj MI et al. | β | 2007 | β |
| Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. | Mwenifumbo JC et al. | β | 2007 | β |
| Non-nicotinic therapies for smoking cessation. | Siu EC et al. | β | 2007 | β |
| Overview of the pharmacogenomics of cigarette smoking. | Ho MK et al. | β | 2007 | β |
| Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. | David SP et al. | β | 2007 | β |
| Racially classified social group tobacco-related health disparities: what is the role of genetics? | Fernander AF | β | 2007 | β |
| The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. | Tyndale RF et al. | β | 2007 | β |
| The role of CYP2A6 in the emergence of nicotine dependence in adolescents. | Audrain-McGovern J et al. | β | 2007 | β |
| Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. | Al Koudsi N et al. | β | 2006 | β |
| Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. | LeSage MG et al. | β | 2006 | β |
| CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. | Kubota T et al. | β | 2006 | β |
| CYP2A6 polymorphisms in Malays, Chinese and Indians. | Nurfadhlina M et al. | β | 2006 | β |
| CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. | Fukami T et al. | β | 2006 | β |
| Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. | Lee AM et al. | β | 2006 | β |
| Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. | Malaiyandi V et al. | β | 2006 | β |
| Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. | Siu EC et al. | β | 2006 | β |
| Recovery of genomic DNA from residual frozen archival blood clots suitable for amplification and use in genotyping assays. | Iovannisci DM et al. | β | 2006 | β |
| Risk factors for tobacco dependence in adolescent smokers. | Karp I et al. | β | 2006 | β |
| The genetics of nicotine dependence: relationship to pancreatic cancer. | MacLeod SL et al. | β | 2006 | β |
| A pharmacogeneticist's look at drug effects and the drug development process: an overview. | Kalow W | β | 2005 | β |
| Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. | Gambier N et al. | β | 2005 | β |
| Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. | Fukami T et al. | β | 2005 | β |
| CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. | Vasconcelos GM et al. | β | 2005 | β |
| CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents. | Huang S et al. | β | 2005 | β |
| Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. | Mwenifumbo JC et al. | β | 2005 | β |
| Genetic diversity and new therapeutic concepts. | Shastry BS | β | 2005 | β |
| Genetic influences on smoking: a brief review. | Al Koudsi N et al. | β | 2005 | β |
| Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. | Malaiyandi V et al. | β | 2005 | β |
| Inter-gene correlation on oligonucleotide arrays: how much does normalization matter? | Gold DL et al. | β | 2005 | β |
| Metabolism and disposition kinetics of nicotine. | Hukkanen J et al. | β | 2005 | β |
| Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. | Swan GE et al. | β | 2005 | β |
| The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary perspective. | Shields AE et al. | β | 2005 | β |
| Three haplotypes associated with CYP2A6 phenotypes in Caucasians. | Haberl M et al. | β | 2005 | β |